BGLAP and type 2 diabetes mellitus: DLCT allows for simultaneous assessment of bone mineral density and fracture risk prediction during these examinations, achieving a “one scan, multiple outcomes” approach.[24] Looking ahead, integrating DLCT-derived parameters with clinical tools such as FRAX scores and biochemical markers (e.g., osteocalcin and advanced glycation end-products) may enable the development of a comprehensive, multidimensional fracture risk prediction model—enhancing personalized prevention and management strategies for skeletal complications in T2DM.[25]